First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The company said the safety profile remained consistent with earlier studies and was considered manageable
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
The approval is supported by results from the Phase 3 SWOG 1826 trial
While overall survival data remain immature, the results pointed to a favourable trend.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
